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adolescents (13–18 years). The effect of combination therapy on risk of weight gain 
was observed against both SSRI monotherapy and SGA monotherapy in multivariable 
logistic regression analyses. Likelihood of gaining weight with combination therapy 
was higher against both SSRI monotherapy (OR = 1.88; 1.69–2.10) and SGA mono-
therapy (OR = 1.52; 1.37–1.68). Long-term combination therapy (>60 days of treat-
ment overlap) resulted into increased risk of weight gain (OR = 1.64; 1.30–2.07) as 
compared to short term uses (> = 14 days and <60 day). CONCLUSIONS: The effect 
of combination therapy on increased risk of weight gain was suggested in the study, 
especially when the combinations were used for long term maintenance. Comprehen-
sive evaluation of other psychotropic combinations on risk of other adverse events is 
needed to be conducted in future.
PIH4
ASSESSMENT OF MATERNAL MORBIDITY DURING LABOR AND 
DELIVERY: EVALUATION OF LENGTH OF DELIVERY HOSPITALIZATION 
STAY OF WOMEN WITH PRE-EXISTING MEDICAL CONDITIONS
Patel A1, Wu WK2
1St. Johns University, Fresh Meadows, NY, USA, 2St. John’s University, Queens, NY, USA
OBJECTIVES: Monitoring maternal morbidity is essential as per Healthy People 2010 
objectives. Maternal morbidity due to pre-existing medical conditions (PEC’s) is found 
to be an important determinant of delivery complications. With limited literature for 
the inﬂuence of PEC’s on obstetric hospitalization, the objective of this study was to 
assess the effects of PEC’s on length of stay (LOS) during child delivery. METHODS: 
The 2006 National Hospital Discharge Survey (NHDS) was used as the data source. 
PEC’s included diagnosis of chronic hypertension, diabetes mellitus, anemia, asthma, 
thyroid disorder or cardiac disease before conception. Cox Proportional Hazards 
Model was performed to ascertain the relationship between PEC’s and LOS in the 
presence of other covariates. The data analysis was conducted using SAS 9.1. 
RESULTS: The 2006 NHDS included records of 39,751 women hospitalized for child 
birth; of which 15.25% (N = 6,063) had diagnosis of one or more PEC’s in contrast 
to 4.9% in early 2000’s. PEC’s group had higher proportion of older women 
(≥35years) (20.32% vs. 16.43%, p < 0.0001) and African-Americans (23.50% vs. 
15.79%, p < 0.0001) compared to the non-PEC’s group. Presence of PEC’s was found 
to be associated with prolonged LOS (hazard ratio = 0.840, p < 0.0001). Among 
hospital characteristics, women delivering in large hospitals (≥500beds) (hazard ratio 
= 0.880, p < 0.0001) and northeastern and southern regions (hazard ratio = 0.813, p 
< 0.0001) had extended LOS. In addition, African-American race (hazard ratio = 
0.863, p < 0.0001) and cesarean delivery (hazard ratio = 0.383, p < 0.0001) were also 
associated with longer LOS. CONCLUSIONS: Women with PEC’s impose signiﬁcant 
health care burden in terms of length of stay during child birth. Access to appropriate 
pre-conception and prenatal care should be ensured to childbearing women, especially 
due to the rising prevalence of PEC’s. Racial and geographical disparities need to be 
examined by policy-makers while framing prophylactic strategies. Future research 
should assess the health care resource utilization due to maternal morbidity from 
pre-conception to postpartum period.
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DIAGNOSIS AND TREATMENT OF WOMEN WITH HYPOACTIVE 
SEXUAL DESIRE DISORDER AND DEPRESSION/ANXIETY
Johnson BH1, Palmer L2, Foley D3
1Thomson Reuters, Washington, DC, USA, 2Thomson Reuters, Washington, DC, USA, 
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OBJECTIVES: The goal of this study is to describe the timing of the Hypoactive Sexual 
Desire Disorder (HSDD) diagnosis with that of depression/anxiety in a subgroup of 
women suffering from both disorders and determine which diagnosis came ﬁrst—
depression/anxiety or HSDD. In addition it describes the use of both antidepressants 
and anxiolytics in this subgroup. METHODS: Marketscan® Research Databases were 
used to identify women aged 18–64 with an ICD-9-CM coded diagnosis of HSDD 
(302.71) from January 1, 1998-December 31, 2007 who also had an ICD-9-CM coded 
diagnosis of depression or anxiety (293.84, 296.2x, 296.3x, 300.0x, 300.4, 309.1, 
311, v79.0). The ﬁrst physician visit with an HSDD diagnosis was the index date. 
Antidepressant and anxiolytic use was examined in the 24-month study period (12-
months before and following index). RESULTS: A total of 957 (24.1%) of 3,975 
women identiﬁed with HSDD also had a diagnosis of anxiety or depression in the 
study period. In this group, 34.7% (n = 332) had a depression/anxiety-coded claim 
appear after their HSDD-coded claim (after cohort), conversely, 65.3% (n = 625) had 
a depression/anxiety-coded claim appear on or before their HSDD-coded claim (before 
cohort). The majority of women in both the after and before cohorts were prescribed 
an antidepressant or anxiolytic in the study period, 78.3% (n = 260) and 86.1% (n 
= 538) respectively. Sixty percent (n = 156) and sixty-ﬁve percent (n = 351) of these 
women went on to discontinue use of the same. CONCLUSIONS: Over 24% of 
women with HSDD also suffer with depression/anxiety. More than one-third of these 
women developed their depression/anxiety diagnosis after being diagnosed with 
HSDD. A larger proportion of women had a diagnosis of depression and/or anxiety 
on or before that of HSDD. This may be evidence that both depression/anxiety and 
HSDD often present in tandem and that doctors feel competent to make such diag-
noses concurrently. Additionally, intervention with antidepressants or anxiolytics 
appear inadequate to treat this population.
PIH6
PREVALENCE AND PREDICTORS OF POLYPHARMACY AMONGST 
ELDERLY PATIENTS: A POPULATION-BASED COHORT STUDY
Slabaugh SL1, Maio V1, Abouzaid S2, Templin M1
1Thomas Jefferson University, Philadelphia, PA, USA, 2Ortho-McNeil Janssen Scientiﬁc Affairs, 
LLC, Titusville, NJ, USA
OBJECTIVES: We sought to evaluate the prevalence of polypharmacy, and to deter-
mine patient characteristics that are predictive of exposure to polypharmacy in the 
elderly population of Emilia-Romagna, Italy. METHODS: We conducted a retrospec-
tive cohort study of the 2007 Emilia-Romagna outpatient pharmacy database linked 
with patient information available from a demographic ﬁle of approximately 1 million 
Emilia-Romagna residents aged ≥65 years. The cohort was comprised of 887,165 
elderly patients who had at least one prescription ﬁlled during the study year. Using 
the World Health Organization’s Deﬁned Daily Dose (DDD) to determine the duration 
of treatment for a given drug, we deﬁned a polypharmacy episode as overlapping 
treatment with 5 or more medications occurring for at least one day. The prevalence 
of polypharmacy was measured together with patient characteristics found to be 
predictive of polypharmacy exposure. RESULTS: A total of 349,689 elderly in the 
population (39.4%) were exposed to at least one episode of polypharmacy. The 
prevalence of polypharmacy substantially increased with age, (32.7% for those ages 
65–74, over 45% for those ages 75+). Over 35% of those exposed to polypharmacy 
were exposed for 101 or more days of the year. The top three classes of medications 
involved in polypharmacy were antithrombotics, peptic ulcer disease and gastro-
esophageal reﬂux disease agents, and angiotensin-converting enzyme inhibitors. Com-
pared to unexposed subjects, elderly exposed to polypharmacy were older, were more 
likely to be male, and had a greater number of chronic conditions. CONCLUSIONS: 
This study provides evidence that the prevalence of polypharmacy in the elderly in 
Emilia-Romagna is substantial. Educational programs targeting primary care physi-
cians should be developed to make them aware of the magnitude of polypharmacy 
phenomenon, as well of patient characteristics associated with polypharmacy to ensur-
ing safe, effective, and appropriate use of medication in the elderly population.
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PREDICTORS OF NON-MEDICAL USE OF PRESCRIPTION DRUGS 
AMONG PREGNANT WOMEN IN THE UNITED STATES
Bali V1, Raisch D2, Moffett M3, Khan N4
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OBJECTIVES: Non-medical use of prescription drugs (NMPUD) is a serious problem 
in the US. This problem is even more concerning among pregnant women since non-
medical use of prescription drugs has the potential to harm both mother and fetus. 
However, our knowledge about the prevalence of NMPUD among pregnant women 
and its predictors is limited. This study attempted to ﬁll these gaps. Objectives of this 
study were: 1) To estimate the prevalence of NMUPD among pregnant women, and 
2) To determine various predictors of NMUPD among pregnant women. METHODS: 
This study used data from 2007 National Survey on Drug Use and Health (NSDUH). 
Sample consisted of non-institutionalized, pregnant women who were 12 years or 
older. Multiple logistic regression analyses which adjusted for the complex survey 
design were conducted to estimate the relationship between NMUPD among pregnant 
women and demographic characteristics. RESULTS: The sample consisted of 956 
respondents out of which 92 (9.62%) had engaged in NMUPD in the past year. 
Among different categories of prescription drugs, prevalence of non-medical use was 
highest for pain relievers (5.27%), followed by tranquilizers (1.65%), stimulants 
(1.93%), and sedatives (0.51%). Results from the logistic regression showed signiﬁ-
cant relationships between past year NMUPD and poor health status (O.R. = 5.28, 
95% CI: 1.37–20.28), past year use of tobacco (O.R. = 2.28, 95% CI: 1.003–5.226), 
and African American race (O.R. = 0.19, 95% CI: 0.06–0.52) or other nonwhite races 
(O.R. = 0.08, 95% CI: 0.02–0.29) at α = 0.05. CONCLUSIONS: Pain relievers are 
used most frequently non-medically by pregnant women when compared to the other 
prescription drugs. Pregnant women, who are white, have poorer health and those 
who smoke are more likely to engage in NMUPD than the others. This study highlights 
the group of pregnant women that are more vulnerable to NMUPD. Physician need 
to be careful while prescribing medication to these high risk groups.
PIH8
DOES TRIAL PARTICIPATION IMPACT ON THE PSYCHOMETRIC 
PROPERTIES OF SELF-REPORT DEPRESSION IN POSTNATAL WOMEN?
Rankin J1, Martin CR2
1University of the West of Scotland, Paisley, UK, 2University of the West of Scotland, 
Ayr, UK
OBJECTIVES: It is assumed within the context of clinical trials that the measurement 
characteristics of self-report outcomes are equivalent. However, little work has been 
conducted to determine if this assumption is supported. The goal of the current study 
was to determine trial allocation may signiﬁcantly impact on the psychometric proper-
ties of a commonly used self-report postnatal depression screening questionnaire. 
METHODS: Utilising data from a prospective randomised controlled trial (RCT) 
investigating the impact of antenatal exercise on psychological well-being, postnatal 
depression was assessed using the Edinburgh Postnatal Depression Scale (EPDS) at the 
12–16 weeks following birth. Structural equation modeling approaches were used to 
investigate the assumption of measurement invariance of the EPDS using a two-
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dimensional model of the instrument with group type (exercise or control) as the 
criterion variable to assess model invariance. RESULTS: A total of 89 participants 
completed the trial of which 48 were in the exercise group. Evidence of variation in 
the factorial structure of the EPDS between groups was found suggesting the invari-
ance assumption may not be supported. CONCLUSIONS: The assumption that the 
outcome measure (EPDS) is invariant between groups within an RCT was not sup-
ported. Further investigation is required to evaluate the impact of outcome measure 
variance on treatment effects in clinical trials where self-report measure data is used 
as primary and/or secondary outcomes.
INDIVIDUAL’S HEALTH – Cost Studies
PIH9
TRENDS IN IUD INSERTIONS AND RELATED MEDICAL EXPENDITURE 
IN THE UNITED STATES: THE POPULATION WITH EMPLOYER-
SPONSORED INSURANCE
Xu X, Macaluso M, Ouyang L, Grosse S
Centers for Disease Control and Prevention, Atlanta, GA, USA
OBJECTIVES: The prevalence of intrauterine device (IUD) use is low among women 
of reproductive age in the United States. The objective of this study was to examine 
the trend in IUD insertions and related medical expenditures between 2002 and 2007 
in a population of women covered by employer-sponsored health insurance (ESI). 
METHODS: We conducted a population-based study using the MarketScan Com-
mercial Claims and Encounter Enrolled Population database. We identiﬁed women, 
15–49 years old who ﬁled a claim for the insertion of an IUD or IUS (the Levonorg-
estrel-releasing IUD) between January 1, 2002 and December 31, 2007. We adopted 
the MarketScan national weights in order to generate nationally representative esti-
mates. RESULTS: The number of new IUD/IUS patients in the ESI-covered population 
doubled, from 70,851 (2/1,000 eligible women) in 2002 to 154,366 (8/1,000) in 2007. 
Meanwhile, the market share of the IUS increased from 35% to 80% of all IUD 
insertions. The mean copayment for IUD (IUS) devices decreased from $13.0 ($14.6) 
in 2002 to $3.5 ($3.6) in 2007 after adjusting for inﬂation (in 2007 dollars), and the 
percent of patients with zero copayment for the device and for the insertion procedure 
increased from 65% to more than 80% and form 58% to 73%, respectively. The 
average net reimbursement for the IUD increased 17.5% between 2002 and 2007, 
from $311.92 to $366.64, while that for the IUS increased 7.5%, from $405.36 to 
$435.49. CONCLUSIONS: The increase in medical expenditures associated with IUD/
IUS insertions from 2002 to 2007 was driven by the growth in IUS insertions. IUDs 
have lower contraceptive failure rates than other reversible contraceptive methods, 
and higher rates of IUD use should lead to fewer unwanted pregnancies. Additional 
research is needed to understand whether the recent growth in IUS insertions is related 
to changing provider attitudes and more favorable insurance coverage.
PIH10
TREATMENT PATTERNS AND ECONOMIC BURDEN OF UTERINE 
FIBROIDS IN A UNITED STATES MANAGED CARE DATABASE
Bapat B1, Davis K1, Bell KF2, Deal LS2, Talbird SE3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Pﬁzer, Collegeville, PA, USA, 3RTI 
Health Solutions, RTP, NC, USA
OBJECTIVES: To document surgical treatment patterns of uterine ﬁbroid (UF) 
patients and total all-cause medical costs for UF patients in real-world practice settings 
using managed care claims data. METHODS: In this retrospective database study, 
women with a UF diagnosis between 15 and 51 years of age were selected between 
2000 and 2006. An index date was deﬁned as the date of ﬁrst observed UF diagnosis. 
All patients were required to have continuous plan enrollment 6 months pre- and 36 
months post-index date. Summary statistics for patient characteristics, probability of 
ﬁrst UF-related surgery, any repeat UF-related surgery, and total medical and phar-
macy costs (2007 US$) incurred 12 months post-index date were generated. RESULTS: 
A total of 109,595 patients met the study inclusion criteria. The mean age at UF 
diagnosis was 43 years and the mean Charlson score was 0.27. Patients with com-
mercial insurance accounted for 91% of the population, while 75% had an HMO 
or PPO plan. The probability of UF-related surgery was 30.2%, 35.0%, and 38.4% 
within the 12-month, 24-month, and 36-month follow-up periods, respectively. 
Among patients with a UF-related surgery during the 36 month follow-up period, 
79.6%, 7.3%, 3.3%, 13.0% had hysterectomy, myomectomy, UAE/UAO, and abla-
tion, respectively. Mean age at ﬁrst surgery (44 years) varied by surgery type with 
younger women more likely to undergo myomectomy. The rate of repeat surgery 
within one year of ﬁrst surgery ranged from 1.6% (hysterectomy) to 10.5% (ablation). 
The mean total cost for all UF patients was $9608, 12 months post-index date. 
CONCLUSIONS: A substantial proportion of patients undergo UF-related surgeries 
within one to three years of diagnosis, with hysterectomy being the most common 
surgery. UF-related surgeries present signiﬁcant clinical and economic implications 
that should be understood by private and public third party payers who bear the 
ﬁnancial burden of UF surgical care.
PIH11
THE BURDEN OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER 
(ADHD) ON PATIENTS HOSPITALIZED WITH A PRIMARY DIAGNOSIS 
OF OPPOSITIONAL DEFIANT DISORDER (ODD)
Meyers J1, Classi P2, Wietecha LA2, Candrilli S1
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Eli Lilly and Company, Indianapolis, 
IN, USA
OBJECTIVES: To assess length of stay (LOS) and costs attributable to ADHD among 
adolescents hospitalized with a primary diagnosis of ODD. METHODS: Patients 
12–17 years old with a primary diagnosis of ODD (ICD-9-CM code 313.81) were 
selected from the 2000 to 2006 Health care Cost and Utilization Project Nationwide 
Inpatient Sample (HCUP-NIS). Patients with a diagnosis of ADHD (ICD-9-CM codes 
314.00 and 314.01) comprised the study cohort and patients without an ADHD 
diagnosis comprised the control cohort. Study measures included demographics, hos-
pital characteristics, admission source, discharge disposition, LOS, and costs. General-
ized linear models accounting for the HCUP-NIS survey design were undertaken to 
adjust LOS and cost estimates. RESULTS: A total of 7,404 and 18,039 patients met 
the inclusion criteria for the study and control cohorts, respectively. Patients in the 
study cohort were 6.8 months younger than patients in the control cohort (13.8 versus 
14.4 years). A higher percentage of patients in the study cohort were male (71.3% 
versus 45.2%) or had Medicaid (57.1% versus 48.6%) compared to the control 
cohort. In both cohorts, the ER was the most common admission source, approxi-
mately 90% of patients had their discharge disposition recorded as routine, and most 
patients were treated in urban, teaching, or large bedsize hospitals. The study cohort 
had longer LOS and higher costs versus the control cohort (mean [SE] 9.48 [0.89] 
days and $8241 [$1356] versus 7.90 [0.59] days and $6466 [$709]). Regression 
analyses found the study cohort had signiﬁcantly longer LOS and higher costs versus 
the control cohort (by 2.5 days and $1338). CONCLUSIONS: Patients hospitalized 
with a primary diagnosis of ODD and a secondary diagnosis of ADHD had signiﬁ-
cantly longer LOS and higher costs compared to patients with ODD but without 
ADHD. Clinicians and health care decision-makers should be aware of the impact 
ADHD has on inpatient stays among patients with ODD.
PIH12
DULOXETINE DOSING PATTERNS AND HEALTH CARE COSTS AMONG 
ELDERLY DIAGNOSED WITH FIBROMYALGIA
Wu N1, Chen SY1, Rao P2, Boulanger L1, Peng X3, Zhao Y3
1Abt Bio-Pharma Solutions, Inc., Lexington, MA, USA, 2Abt Bio-Pharma Solutions, Inc, 
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OBJECTIVES: This study employed a retrospective cohort design to examine patterns 
of duloxetine utilization and health care costs among elderly ﬁbromyalgia patients. 
METHODS: Pharmacy and medical claims were analyzed for ﬁbromyalgia patients 
aged 65+ with Medicare supplemental insurance who initiated duloxetine in 2006. 
The index date was deﬁned as the dispense date of the ﬁrst duloxetine prescription 
ﬁlled, with no duloxetine coverage in the prior 90 days. Patients were required to have 
at least 30 supply days of duloxetine in the 12 months post-index period. Individuals 
with any diagnosis of diabetic peripheral neuropathic pain or depression during the 
12 months pre-index period were excluded. Five study cohorts were constructed based 
on the index dosage: <30 mg, 30 mg, 31–59 mg, 60 mg, and >60 mg. Patterns of dulox-
etine use including changes in dosage, average daily dose (ADD), adherence to dulox-
etine (medication possession ratio≥0.8 as high adherence) were examined across study 
cohorts. Regression models were performed to estimate the differences in health care 
costs. RESULTS: A total of 566 ﬁbromyalgia patients were included, with 41, 163, 
47, 294 and 21 in the <30 mg, 30 mg, 31–59 mg, 60 mg, and >60 mg cohorts, respec-
tively. A total of 31.4% of patients experienced any dosage changes (increased dosage: 
25.8%; decreased dosage: 15.7%). Among those who changed dosage, patients in the 
31–59 mg cohort had the shortest time to change (81 days), and patients in the <30 mg 
cohort had the longest (149 days) time. ADD trended upward as index dose increased. 
Compared with patients in the 60 mg cohort, those in the <30 mg and >60 mg cohorts 
were less likely to be adherent (odds ratios 0.40 and 0.30, respectively, both p < 0.05). 
Post-index total health care costs were similar across cohorts. CONCLUSIONS: 
Dosage changes occurred most quickly in ﬁbromyalgia patients with an index dose of 
31–59 mg of duloxetine. Duloxetine ADD and adherence differ by index dosage, while 
health care costs remain similar.
PIH13
HEALTH CARE UTILIZATION AND COSTS FOR THE TREATMENT OF 
HYPOACTIVE SEXUAL DESIRE DISORDER
Palmer L1, Johnson BH1, Foley D2
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OBJECTIVES: Hypoactive sexual desire disorder (HSDD) is characterized by persis-
tent/ recurring deﬁciency of sexual fantasies or thoughts, and/or the absence of desire 
for sexual activity. Despite the potentially high prevalence of the condition, few studies 
have evaluated the cost of treating women with HSDD. The current study describes 
health care utilization and costs among women suffering from HSDD relative to 
women without evidence of female sexual dysfunction (FSD). METHODS: Women 
aged 18–64 with a diagnosis of HSDD (ICD-9-CM: 302.71) were identiﬁed using the 
Marketscan® Commercial Claims and Encounters Databases from Thomson Reuters. 
Women were identiﬁed between January 1, 1998-December 31, 2007 and were 
matched 1:3 to women without FSD (ICD-9-CM: 302.7x; 306.51) based on age, 
health plan type and months with medical/pharmacy beneﬁts. Utilization and costs 
were evaluated during the 12, 24 and 36- month periods following HSDD diagnosis. 
